About Us

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.

Solutions

We are dedicated to helping patients at all stages of cancer live longer and healthier, through the power of blood tests and the data they unlock. Today our tests help inform treatment decisions for patients with advanced cancer. Our tests also detect residual and recurrent disease for patients with early-stage cancer and will soon screen to find cancer at its earliest and most treatable.

0
+
Clinical Samples Reported
0
+
Biopharma Partners
0
+
Ordering Oncologists
0
+
Peer-reviewed publications

Ordering Process

order icon

Physician to request a kit online or contact our local partner

blood donation icon

Blood/Tissue samples to be taken from the patient

email icon

Kit to be stored at room temperature and couriered to the laboratory

7 days icon

Test report to be emailed to physicians in 7 days upon sample receipt in the laboratory. 1,2

1. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. February 2023.
2. FDA News Release. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test. August 7, 2020. Accessed June 29, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test

News & Events

We Thank Oncologists, We Serve Patients
GH AMEA
A HUGE THANK YOU to all oncologists, researchers and biopharma companies who have worked closely with us this year. Thank you for your…
ESMO Asia 2023 Poster Presentations
GH AMEA
Congratulations to these authors! ESMO Asia 2023 saw four poster presentations and one mini oral session where the data from Guardant Health’s tests…
Adicon offers GuardantOMNI® liquid biopsy test for clinical trials in China with equivalent performance to Guardant Health’s US-based laboratory test
GH AMEA
HANGZHOU, China (April 2, 2024) --Adicon Holdings Limited, a leading independent clinical laboratory company, announced today it now offers GuardantOMNI®, a 500-gene panel…

Where to Find Us

Search Location

Category

Distance Range Radius: KM

Status

Get Your Directions

Show Distance In

Use my location to find the closest Service Provider near me

Number of Countries: 0
Loading...

Directions

Message us